鹭燕医药发布前三季度业绩，归母净利润2.2亿元，同比下降14.64%

Core Viewpoint - Luyuan Pharmaceutical (002788.SZ) reported a slight increase in revenue for the first three quarters of 2025, but net profit experienced a significant decline compared to the previous year [1] Financial Performance - The company achieved an operating revenue of 15.855 billion yuan, representing a year-on-year growth of 2.87% [1] - The net profit attributable to shareholders of the listed company was 220 million yuan, reflecting a year-on-year decrease of 14.64% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was also 220 million yuan, showing a decline of 15.14% year-on-year [1]